Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
Net revenues	$ 82,888	$ 33,087	$ 15,490
Cost of revenues	39,870	20,610	10,036
Impairment of field equipment	6,412
Gross profit	36,606	12,477	5,454
Operating costs and expenses:
Research, development and clinical trials	41,467	43,748	40,381
Sales and marketing	59,449	38,861	21,177
General and administrative	51,007	33,864	24,052
Total operating costs and expenses	151,923	116,473	85,610
Operating loss	(115,317)	(103,996)	(80,156)
Financial expenses, net	(6,147)	(3,151)	(144)
Loss before income taxes	(121,464)	(107,147)	(80,300)
Income taxes	10,381	4,434	382
Net loss	$ (131,845)	$ (111,581)	$ (80,682)
Basic and diluted net loss per ordinary share	$ (1.54)	$ (3.67)	$ (6.46)
Weighted average number of ordinary shares used in computing basic and diluted net loss per share	85,558,448	30,401,603	12,490,017